Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial.

ABSTRACT:

Rationale

Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.

Objectives

To assess the effects of bimagrumab on skeletal muscle mass and function in patients with chronic obstructive pulmonary disease (COPD) and reduced skeletal muscle mass.

Methods

Sixty-seven patients with COPD (mean FEV₁, 1.05 L [41.6% predicted]; aged 40-80 yr; body mass index < 20 kg/m² or appendicular skeletal muscle mass index ≤ 7.25 [men] and ≤ 5.67 [women] kg/m²), received two doses of either bimagrumab 30 mg/kg intravenously (n = 33) or placebo (n = 34) (Weeks 0 and 8) over 24 weeks.

Measurements and main results

We assessed change

SUBMITTER: Polkey MI 

PROVIDER: S-EPMC6363975 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature